Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Li Zhang et al.|The Lancet Oncology|2011Cited by 4.1k
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G. Chen, Changxuan You, J. Feng et al.|Annals of Oncology|2013Cited by 120
Role of IL-17 in LPS-induced acute lung injury: an<i>in vivo</i>studyQi Ding, Jianan Huang|Oncotarget|2017Cited by 60
Moesin Is a Novel Biomarker of Endothelial Injury in SepsisYikun Chen, Jianan Huang|Journal of Immunology Research|2021Cited by 15
Heavily Er2O3 doped TeO2 based glass-ceramics with large grain size and high transparency for broadband ∼1.55 and efficient ∼3.5 μm fluorescenceSiyu Zhu, Liaolin Zhang, Junfu Song et al.|Physica B Condensed Matter|2022Cited by 4